Literature DB >> 28488155

Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.

Traci R Rieckmann1, Nicholas Gideonse2, Amanda Risser2, Jennifer E DeVoe3, Amanda J Abraham4.   

Abstract

Research has examined the safety, efficacy, feasibility, and cost-effectiveness of buprenorphine for the treatment of opioid dependence, but few studies have examined patient and provider experiences, especially in community health centers. Using de-identified electronic health record system (EHRS) data from 70 OCHIN community health centers (n = 1825), this cross-sectional analysis compared the demographics, comorbidities, and service utilization of patients receiving buprenorphine to those not receiving medication-assisted treatment (MAT). Compared to non-MAT patients, buprenorphine patients were younger and less likely to be Hispanic or live in poverty. Buprenorphine patients were less likely to have Medicaid insurance coverage, more likely to self-pay, and have private insurance coverage. Buprenorphine patients were less likely to have problem medical comorbidities or be coprescribed high-risk medications. It is important for providers, clinic administrators, and patients to understand the clinical application of medications for opioid dependence to ensure safe and effective care within safety net clinics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28488155     DOI: 10.1007/s11414-017-9553-z

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


  57 in total

1.  Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.

Authors:  Daniel Polsky; Henry A Glick; Jianing Yang; Geetha A Subramaniam; Sabrina A Poole; George E Woody
Journal:  Addiction       Date:  2010-07-12       Impact factor: 6.526

2.  Smoking and opioid detoxification: behavioral changes and response to treatment.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; David A Gorelick
Journal:  Nicotine Tob Res       Date:  2013-04-09       Impact factor: 4.244

3.  Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients.

Authors:  Joseph Tkacz; Joseph Volpicelli; Hyong Un; Charles Ruetsch
Journal:  J Subst Abuse Treat       Date:  2013-11-12

4.  Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Authors:  Ira L Mintzer; Mark Eisenberg; Maria Terra; Casey MacVane; David U Himmelstein; Steffie Woolhandler
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

5.  The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study.

Authors:  Andrea A Howard; Donald R Hoover; Kathryn Anastos; Xi Wu; Qiuhu Shi; Howard D Strickler; Stephen R Cole; Mardge H Cohen; Andrea Kovacs; Michael Augenbraun; Patricia S Latham; Phyllis C Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

6.  From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

Authors:  Walter Ling; Petra Jacobs; Maureen Hillhouse; Albert Hasson; Christie Thomas; Thomas Freese; Steven Sparenborg; Dennis McCarty; Roger Weiss; Andrew Saxon; Allan Cohen; Michele Straus; Gregory Brigham; David Liu; Paul McLaughlin; Betty Tai
Journal:  J Subst Abuse Treat       Date:  2010-06

7.  Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.

Authors:  P M Monti; D J Rohsenow; R M Swift; S B Gulliver; S M Colby; T I Mueller; R A Brown; A Gordon; D B Abrams; R S Niaura; M K Asher
Journal:  Alcohol Clin Exp Res       Date:  2001-11       Impact factor: 3.455

8.  Gender and comorbidity among individuals with opioid use disorders in the NESARC study.

Authors:  Christine E Grella; Mitchell P Karno; Umme S Warda; Noosha Niv; Alison A Moore
Journal:  Addict Behav       Date:  2009-01-30       Impact factor: 3.913

Review 9.  Disparities in Latino substance use, service use, and treatment: implications for culturally and evidence-based interventions under health care reform.

Authors:  Erick G Guerrero; Jeanne C Marsh; Tenie Khachikian; Hortensia Amaro; William A Vega
Journal:  Drug Alcohol Depend       Date:  2013-08-02       Impact factor: 4.492

10.  Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems.

Authors:  Theresa A Rowe; Janet S Jacapraro; Darius A Rastegar
Journal:  Addict Sci Clin Pract       Date:  2012-10-29
View more
  5 in total

1.  The Future of Research on Alcohol Health Disparities: A Health Services Research Perspective.

Authors:  Joseph E Glass; Emily C Williams
Journal:  J Stud Alcohol Drugs       Date:  2018-03       Impact factor: 2.582

2.  Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida.

Authors:  Amanda Sharp; Melissa Carlson; Veronica Howell; Kathleen Moore; Zev Schuman-Olivier
Journal:  J Subst Abuse Treat       Date:  2020-12-11

3.  Predictors of Medication-Assisted Treatment Initiation for Opioid Use Disorder in an Interdisciplinary Primary Care Model.

Authors:  Rebecca E Cantone; Brian Garvey; Allison O'Neill; Joan Fleishman; Deborah Cohen; John Muench; Steffani R Bailey
Journal:  J Am Board Fam Med       Date:  2019 Sep-Oct       Impact factor: 2.657

4.  Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network.

Authors:  Kevin A Hallgren; Elizabeth Witwer; Imara West; Laura-Mae Baldwin; Dennis Donovan; Brenda Stuvek; Gina A Keppel; Brenda Mollis; Kari A Stephens
Journal:  J Subst Abuse Treat       Date:  2019-11-16

Review 5.  Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.

Authors:  Amanda J Abraham; Christina M Andrews; Samantha J Harris; Peter D Friedmann
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.